Modern Vaccines Adjuvants & Delivery Systems

4-6 July 2012, Eigtveds Pakhus, Copenhagen, Denmark

  • Increase font size
  • Default font size
  • Decrease font size

Poster Session

Poster 101
‘Charge-dependent interactions of liposomal vaccine adjuvants with mucosal airway epithelial cells’
Pall Thor Ingvarsson et al. (University of Copenhagen, Copenhagen, Denmark)

Poster 102
‘The novel adjuvant PCEP induces cell recruitment and activates inflammasomes in dendritic cells’
Sunita Awate et al. (VIDO, University of Saskatchewan, Saskatoon, Canada)

Poster 103
‘Advancing vaccine formulations of importance to developing countries using new and existing adjuvant technologies’
Jeremy Blum (PATH, Seattle, Washington, USA)

Poster 104
‘A novel intranasal respiratory syncytial virus (RSV)-virosomal vaccine with incorporated TLR2 and NOD2 ligands induces protective mucosal and systemic immune responses’
Muhammad Shafique et al. (UMC/University of Groningen, Groningen, The Netherlands)

Poster 105
‘Oxidation-sensitive polymersomes for both passive and active delivery to the cytosol of antigen presenting cells’
Evan A. Scott et al. (EPFL, Lausanne, Switzerland)

Poster 106
‘Comparison of adjuvants for antibody mediated immunogenicity in rhesus macaques upon immunization with a staphyloccal test antigen’
Amita Joshi et al. (Merck Research Laboratories, West Point, Pennsylvania, USA)

Poster 107
‘Targeting the sentinel lymph node enhances the therapeutic efficacy of a nanoparticle cancer vaccine’
Laura Jeanbart et al. (EPFL, Lausanne, Switzerland)

Poster 108
‘Preparation process and formulation characterization of DDA/TBD/poly(I:C) liposomes at different lipid-to-poly (I:C) ratios using DLS, Nanosight, SAXS, Cryo-TEM, and field flow fractionation’
Fabrice Rose et al. (University of Copenhagen, Copenhagen, Denmark)

Poster 109
‘Lead antigens Pfs25-EPA and CSP-EPA for a vaccine to interrupt malaria transmission evaluated for stability and immunogenicity in formulations with alhydrogel and CAF01’
Kelly M. Rausch et al. (NIH/NIAID/LMIV, Rockville, Maryland, USA)

Poster 110
‘Protein antigen adsorption to the CAF/NAF liposomal adjuvants: Effect of liposome charge, bilayer fluidity, pI and antigen-to-lipid ratio’
Mette Hamborg et al. (University of Copenhagen, Copenhagen, Denmark)

Poster 111
‘Characterisation of OspC liposome-based experimental vaccine with entrapped lipophilic derivatives of norAbuMDP against Borrelia burgdorferi
Josef Masek et al. (Veterinary Research Institute, Brno, Czech Republic)

Poster 112
‘Early transcriptional response to ISCOM-Matrix at the site of administration and in the draining lymph node after intramuscular injection in pigs’
Viktor Ahlberg et al. (Swedish University of Agricultural sciences, Uppsala, Sweden)

Poster 113
‘Investigating methods to manufacture liposomal adjuvants with entrapped antigens’
Alexander Wilkinson et al. (Aston University, Birmingham, UK)

Poster 114
‘A novel prime-boost immunisation strategy against HBV, using cationic liposomes as delivery system for pDNA and protein’
Behfar Moghaddam et al. (Aston University, Birmingham, UK)

Poster 115
‘Effect of CpG on prophylactic and therapeutic application of allergen via laser-generated micropores’
Sandra Scheiblhofer et al. (University of Salzburg, Salzburg, Austria)

Poster 116
‘TRANSVAC: European network of vaccine research and development’
Regitze Louise Thogersen et al. (European Vaccine Initiative, Heidelberg, Germany)

Poster 117
‘Formulation of MIDGE(-Th1)® DNA vectors with synthetic adjuvant SAINT-18’
Anne Endmann et al. (MOLOGEN AG, Berlin, Germany)

Poster 118
‘The oral biodistribution of free H3N2 and bilosome entrapped antigen’
Jitender Singh Wilkhu et al. (Aston University, Birmingham, UK)

Poster 119
‘Influenza virosomes as a peptide vaccine delivery system’
Peter Soema et al. (National Institute for Public Health & the Environment, Bilthoven, The Netherlands)

Poster 120
‘DNA vaccine formulation to enhance Th1 immune responses against M. Tuberculosis
Johanna Poecheim et al. (University of Geneva-University of Lausanne, Geneva, Switzerland)

Poster 121
‘Evaluation of Streptococcus suis subunit vaccines with various adjuvants’
Chun-yen Chu et al. (National Pingtung University of Science & Technology, Neipu, Pingtung, Taiwan)

Poster 122
‘Chicken immunization against influenza with DNA vaccine encoding hemagglutinin from H5N1 influenza virus’
Anna Stachyra et al. (Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland)

Poster 123
‘Achieving mucosal and systemic immunity by exploiting vitamin A metabolites as vaccine co-adjuvants’
Silvia Vendetti et al. (ISS, Rome, Italy)

Poster 124
‘Challenges in sterile filtration of novel adjuvants’
Sharon Oba and Susan Giudetti (EMD Millipore, USA)

Poster 125
‘Optimised allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass pollen allergy’
L. Lund et al. (ALK-Abello A/S, Hoersholm, Denmark)

Poster 126
‘Influence of phosphate salts and alum content on to the immunogenicity of a Dermatophagoides siboney AFPL1-adjuvanted vaccine’
Roxana Samalea et al. (National Center of Bioproducts, Bejucal, Cuba)


MVADS 2012 Sponsors

  • Infectious Disease Research Institute
  • Seppic
  • European Adjuvant Advisory Committee
  • Immune Design
  • Cytos Biotechnology
  • ALK Abello
  • ApoVax
  • Ichor Medical Systems
  • Brenntag
  • Retroscreen Virology
  • Eurocine
  • Wittycell
  • Sanofi Pasteur
  • Intercell
  • Statens Serum Institut
  • Pfizer
  • European Vaccine Initiative EVI
  • CSL
  • Viscogel
  • Immune Solutions
  • Inovio Pharmaceuticals
  • Isconova
  • Crossbeta Biosciences
  • Dynavax Technologies
  • Mucosis
  • Novartis Vaccines
  • Aldevron
  • European Vaccine Initiative PHARVAT
  • European Vaccine Initiative TRANSVAC

MVADS 2012 Downloads

MVADS 2012 Leaflet

MVADS 2012 Mailing List

E-mail Address
What is 1+4-2?